Epidemiology Study of Malaria Transmission Intensity in Africa
Trial overview
Number of Subjects With Plasmodium Falciparum (P. Falciparum) Parasitaemia (PFP), for each Survey
Timeframe: At each Survey visit
Number of Subjects With Plasmodium Falciparum (P. Falciparum) Parasitaemia (PFP), According to Annual Age for Children of 4 Years or Less, for each Survey
Timeframe: At each Survey visit
Number of subjects with anemia and severe anemia for each Survey
Timeframe: During the survey period (approximatively 1 year)
Number of Subjects With Anti-malarial Therapy in Survey 1, according to parasite density
Timeframe: During the survey period (approximatively 1 year)
Number of Subjects With Anti-malarial Therapy in Survey 2, according to parasite density
Timeframe: During the survey period (approximatively 1 year)
Number of Subjects With Anti-malarial Therapy in Survey 3, according to parasite density
Timeframe: During the survey period (approximatively 1 year)
Number of Subjects With Anti-malarial Therapy in Survey 4, according to parasite density
Timeframe: During the survey period (approximatively 1 year)
Mean number of Days with Malaria Treatment at Survey 1
Timeframe: During the 14 day-period before the malaria treatment
Mean number of Days with Malaria Treatment at Survey 2
Timeframe: During the 14 day-period before the malaria treatment
Mean number of Days with Malaria Treatment at Survey 3
Timeframe: During the 14 day-period before the malaria treatment
Mean number of Days with Malaria Treatment at Survey 4
Timeframe: During the 14 day-period before the malaria treatment
Number of subjects with fever in the last 24 hours or at visit during Survey 1
Timeframe: In the last 24 hours or at the survey visit
Number of subjects with fever in the last 24 hours or at visit during Survey 2
Timeframe: In the last 24 hours or at the survey visit
Number of subjects with fever in the last 24 hours or at visit during Survey 3
Timeframe: In the last 24 hours or at the survey visit
Number of subjects with fever in the last 24 hours or at visit during Survey 4
Timeframe: In the last 24 hours or at the survey visit
Mean number of Days with Fever at Survey 1
Timeframe: During the survey period (approximatively 1 year)
Mean number of Days with Fever at Survey 2
Timeframe: During the survey period (approximatively 1 year)
Mean number of Days with Fever at Survey 3
Timeframe: During the survey period (approximatively 1 year)
Mean number of Days with Fever at Survey 4
Timeframe: During the survey period (approximatively 1 year)
Axillary temperature at visit in Survey 1
Timeframe: At Survey visit
Axillary temperature at visit in Survey 2
Timeframe: At Survey visit
Axillary temperature at visit in Survey 3
Timeframe: At Survey visit
Axillary temperature at visit in Survey 4
Timeframe: At Survey visit
Number of subjects living in the same house at Survey 1
Timeframe: At Survey visit
Number of subjects living in the same house at Survey 2
Timeframe: At Survey visit
Number of subjects living in the same house at Survey 3
Timeframe: At Survey visit
Number of subjects living in the same house at Survey 4
Timeframe: At Survey visit
Mean number of subjects living in the same house at Survey 1
Timeframe: At Survey visit
Mean number of subjects living in the same house at Survey 2
Timeframe: At Survey visit
Mean number of subjects living in the same house at Survey 3
Timeframe: At Survey visit
Mean number of subjects living in the same house at Survey 4
Timeframe: At Survey visit
Number of subjects by localisation and type of location at Survey 1
Timeframe: At Survey visit
Number of subjects by localisation and type of location at Survey 2
Timeframe: At Survey visit
Number of subjects by localisation and type of location at Survey 3
Timeframe: At Survey visit
Number of subjects by localisation and type of location at Survey 4
Timeframe: At Survey visit
Number of subjects by house construction material regarding walls and floor at Survey 1
Timeframe: At Survey visit
Number of subjects by house construction material regarding walls and floor at Survey 2
Timeframe: At Survey visit
Number of subjects by house construction material regarding walls and floor at Survey 3
Timeframe: At Survey visit
Number of subjects by house construction material regarding walls and floor at Survey 4
Timeframe: At Survey visit
Number of subjects classified by house construction material regarding roof, window/eaves and nets at Survey 1
Timeframe: At Survey visit
Number of subjects classified by house construction material regarding roof, window/eaves and nets at Survey 2
Timeframe: At Survey visit
Number of subjects classified by house construction material regarding roof, window/eaves and nets at Survey 3
Timeframe: At Survey visit
Number of subjects classified by house construction material regarding roof, window/eaves and nets at Survey 4
Timeframe: At Survey visit
Number of subjects classified by house information regarding main source of the drinking water and presence of electricity at Survey 1
Timeframe: At Survey visit
Number of subjects classified by house information regarding main source of the drinking water and presence of electricity at Survey 2
Timeframe: At Survey visit
Number of subjects classified by house information regarding main source of the drinking water and presence of electricity at Survey 3
Timeframe: At Survey visit
Number of subjects classified by house information regarding main source of the drinking water and presence of electricity at Survey 4
Timeframe: At Survey visit
Number of subjects with malaria prevention measures (MPM) at each survey
Timeframe: At each Survey visit
Number of subjects with Plasmodium species other than P. falciparum at Survey 1
Timeframe: At Survey visit
Number of subjects with Plasmodium species other than P. falciparum at Survey 2
Timeframe: At Survey visit
Number of subjects with Plasmodium species other than P. falciparum at Survey 3
Timeframe: At Survey visit
Number of subjects with Plasmodium species other than P. falciparum at Survey 4
Timeframe: At Survey visit
Number of subjects with serious adverse events (SAEs) related to study procedure for each survey
Timeframe: At each Survey visit
Participation criteria
- Subjects who the investigator believes that they and/or their parent(s)/Legally Acceptable Representative(s) can and will comply with the requirements of the protocol.
- A male or female 6 months or older at the time of survey.
- Child in care.
- Previous or current participation in any malaria vaccine trial.
- Subjects who the investigator believes that they and/or their parent(s)/Legally Acceptable Representative(s) can and will comply with the requirements of the protocol.
- A male or female 6 months or older at the time of survey.
- Written informed consent obtained from the subject/from the parent(s)/ Legally Acceptable Representative(s) of the subject.
- Child in care.
- Previous or current participation in any malaria vaccine trial.
Trial location(s)
Study documents
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.